Company Filing History:
Years Active: 2023
Title: Haijun Sun: Innovator in Cancer Treatment
Introduction
Haijun Sun is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of binding molecules that target the human epidermal growth factor receptor (EGFR). His work is expected to have a profound impact on cancer treatment.
Latest Patents
Haijun Sun holds a patent for EGFR binding molecules. This patent relates to specific binding members that bind to the human epidermal growth factor receptor (EGFR). The specific binding members include an EGFR antigen-binding site, which may be located in two or more structural loops of a CH3 domain. These binding members are anticipated to be useful in treating cancers that express EGFR.
Career Highlights
Throughout his career, Haijun Sun has worked with prominent companies in the biotechnology sector, including F-star Therapeutics, Inc. and F-star Biotechnology Ltd. His experience in these organizations has allowed him to advance his research and contribute to innovative solutions in cancer therapy.
Collaborations
Haijun Sun has collaborated with talented individuals such as Mihriban Tuna and Kin-Mei Leung. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking technologies.
Conclusion
Haijun Sun is a distinguished inventor whose work on EGFR binding molecules holds promise for cancer treatment. His contributions to biotechnology and collaborations with industry professionals underscore his commitment to innovation in healthcare.